Highest-materiality recent filing
All 10 director nominees elected with 95%+ votes for each; broker non-votes of 16.4M shares.
BBWI Q1 sales down 3%, adjusted EPS $0.32 beats guidance; CFO Boratto to step down June 12
Q1 net sales $1.378B (-3% YoY); GAAP EPS $0.90, adjusted EPS $0.32 (beating guidance).
BBWI Q4 adj EPS $2.05 beats; FY2026 sales guide down 2.5-4.5%, adj EPS $2.40-2.65
Q4 net sales $2.724B (-2% YoY); adj EPS $2.05 vs prior year $2.09 but above company guidance.
Bath & Body Works calls for redemption of all outstanding 6.694% Senior Notes due 2027
Notice of redemption for any and all outstanding 6.694% Senior Notes due 2027 (CUSIP unknown).
Bath & Body Works Chief Legal Officer Michael Wu to depart; search underway for successor
Michael Wu ceased as Chief Legal Officer and Corporate Secretary effective February 24, 2026.
Bath & Body Works launches transformation plan; Q3 EPS $0.37, cuts FY25 guidance
Q3 net sales $1.594B (-1% YoY); GAAP EPS $0.37 ($0.35 adj); operating income $161M vs $218M prior year.
BBWI Q2 net sales +1.5% to $1.55B, adj EPS $0.37 (high end); raises FY adj EPS low end
Q2 GAAP EPS $0.30 vs $0.68 last year; adj EPS $0.37 flat YoY.
All nine director nominees elected; Alessandro Bogliolo received 8.6M against votes, lowest support among nominees.
Bath & Body Works Q1 net sales up 3% to $1.42B, EPS up 29% to $0.49; maintains FY guidance
Net sales $1,424M (+2.9% YoY); EPS $0.49 (+29% YoY) vs $0.38 prior year.
Bath & Body Works amends and restates senior secured ABL facility with five-year maturity
Facility matures five years after closing, with springing maturity 91 days prior to certain senior note maturities.
Bath & Body Works names Daniel Heaf CEO; Q1 EPS $0.49 beats high-end guidance
Daniel Heaf appointed CEO effective May 16, 2025, replacing Gina Boswell who stepped down.
Bath & Body Works hosts investor tour at Beauty Park; presentation available online
Investor tour at Beauty Park in Columbus, Ohio on April 17, 2025 at 10 a.m. ET.
CEO Gina Boswell to take temporary absence for scheduled surgery starting March 20
Boswell will be out of the office for up to four weeks starting March 20, 2025, followed by remote work.
Bath & Body Works reaffirms Q1 and FY2025 guidance at BofA conference
Reaffirmed Q1 2025 net sales growth of 1-3% and EPS of $0.36-$0.43 per diluted share.
Bath & Body Works Q4 2024 beats guidance; provides FY2025 outlook
Q4 net sales $2,788M (down 4.3% YoY on 13 vs 14 weeks); GAAP EPS $2.09 vs $2.55.
CHRO Deon Riley leaves Bath & Body Works effective Jan 31, 2025
Deon Riley ceased as Chief Human Resources Officer on Jan 31, 2025.
Bath & Body Works redeems all outstanding 9.375% Senior Notes due 2025 on Jan 30
Notice of redemption for any and all outstanding 9.375% Senior Notes due 2025.
Bath & Body Works Q3 sales up 3% to $1.61B, EPS $0.49 beats guidance; raises FY guidance
Q3 net sales $1,610M (+3% YoY); EPS $0.49 vs $0.52 ($0.48 adjusted) prior year, exceeding guidance.
Julie Rosen steps down as Bath & Body Works President, Retail; role eliminated
Rosen ceased as President, Retail effective Sep 25, 2024; will be advisory until Oct 22 then separate.
Bath & Body Works Q2 adjusted EPS $0.37 beats guidance; lowers FY2024 outlook
Q2 net sales $1,526M, down 2.1% YoY; adjusted EPS $0.37 vs. $0.40 last year, above guidance.
Bylaws amended: advance notice for 2025 annual meeting must be received between Feb 27 and Mar 29, 2025.
Bath & Body Works Q1 EPS $0.38 beats high-end guidance; narrows FY2024 range upward
Q1 net sales $1,384M (-0.9% YoY) above guidance; diluted EPS $0.38 (GAAP), up 9% YoY.
Bath & Body Works director Thomas J. Kuhn resigns; board reduced to 12
Thomas J. Kuhn resigned from the Board effective April 20, 2024.
Two directors not standing for re-election at Bath & Body Works 2024 Annual Meeting
Patricia S. Bellinger and Michael G. Morris will not stand for re-election to the Board of Directors.
BBWI Q4 EPS beat; new $500M buyback; FY2024 sales guidance -3% to flat
Q4 net sales $2.912B (+0.8% YoY; extra week contributed ~$80M); adjusted EPS $2.06 vs guidance $1.87.
Bath & Body Works reaffirms Q4 and FY 2023 net sales guidance at Morgan Stanley conference
Reaffirmed Q4 2023 net sales guidance: decline of 1% to 5%.
Bath & Body Works beats Q3 EPS guidance; raises FY2023 adj. EPS midpoint
Q3 net sales $1.562B, down 2.6% YoY; GAAP EPS $0.52 vs $0.40 prior year.
Bath & Body Works Q2 sales down 3.6% to $1.559B, adj EPS $0.40 beat; FY guide raised
Net sales $1.559B (-3.6% YoY), in line with expectations.
Bath & Body Works appoints Eva Boratto as CFO effective August 1, 2023
Eva Boratto named CFO, succeeds Wendy Arlin who steps down July 29, 2023.
All 13 directors elected; highest 'for' vote 190.8M, lowest 183.5M; broker non-votes 13.5M.
Bath & Body Works Q1 EPS beats guidance; full-year EPS outlook raised
Q1 net sales $1.396B, down 4% YoY; EPS $0.35 vs $0.64 prior year.
Wendy Arlin to step down as CFO effective July 29, 2023 or earlier if successor named; search initiated.
Bath & Body Works appoints Thomas J. Kuhn to board; Third Point drops proxy contest
Thomas J. Kuhn appointed as independent director effective March 10, 2023; brings 35 years of financial and legal advisory experience.
Bath & Body Works Q4 sales down 5% to $2.889B; EPS $1.86 vs $2.27; guides FY23 EPS $2.50-$3.00
Q4 net sales $2.889B (-5% YoY); operating income $652.7M vs $879.2M; net income $428.2M vs $592.6M.
Bath & Body Works appoints Hershey CFO Steve Voskuil as independent director
Voskuil, CFO of Hershey since 2019, appointed effective Feb 21, 2023.
Bath & Body Works appoints Lucy Brady to Board of Directors
Lucy Brady, President of Grocery & Snacks at Conagra Brands, appointed as independent director.
Bath & Body Works Q3 EPS $0.40 beats guidance; raises FY2022 EPS outlook
Q3 net sales $1.60B, down 5% YoY from $1.68B; EPS $0.40 vs guidance of $0.10-$0.20.
Bath & Body Works appoints Gina Boswell as CEO effective December 1, 2022
Gina Boswell named CEO and board member; starts December 1, 2022.
Bath & Body Works Q2 EPS $0.52, sales down 5%; COO resigns, 130 roles cut
Q2 net sales $1.618B (-5% YoY); diluted EPS $0.52 vs $0.77 prior year.
Bath & Body Works commences rescission offer for 136K shares omitted from S-8 registration
Up to 136,380 shares offered under 401(k) plan were inadvertently omitted from S-8 registration.
Bath & Body Works lowers Q2 and FY 2022 guidance on inflation pressure
Q2 sales now expected down 6-7% YoY vs prior guide of low single-digit increase.
Bath & Body Works beats Q1 guidance but cuts FY2022 EPS outlook to $3.80-$4.15
Q1 net sales $1.450B (-1% YoY); adjusted EPS $0.64 (+7% YoY), ahead of guidance.
CEO Meslow steps down for health; Sarah Nash named interim CEO
Andrew Meslow resigned as CEO and director on May 12, 2022 due to health; Executive Chair Sarah Nash appointed interim CEO.
CEO Andrew Meslow to depart May 12; receives $7M severance, extended non-compete
CEO Andrew M. Meslow resigns effective May 12, 2022 due to health reasons.
Bath & Body Works appoints Alessandro Bogliolo and Juan Rajlin to Board
Former Tiffany CEO Alessandro Bogliolo and Alphabet Treasurer Juan Rajlin join BBWI Board as independent directors.
CEO Andrew Meslow will step down effective May 12, 2022 due to health reasons; remains CEO through that date.
BBWI reports record Q4/FY21 earnings, CEO Meslow to step down in May due to health
Q4 net sales $3.027B (+11% YoY); GAAP EPS $2.27, adjusted EPS $2.30 (+17% YoY).
Bath & Body Works enters $1 billion accelerated share repurchase with JPMorgan
Agreement with JPMorgan to repurchase $1 billion of BBWI common stock, announced February 2, 2022.
Director Robert H. Schottenstein will not seek re-election at 2022 Annual Meeting
Schottenstein's decision is not due to a disagreement with the company.
Bath & Body Works Q4 record sales $3.027B (+11%); EPS ~$2.25; $1.5B buyback & 33% dividend hike
Q4 net sales $3.027B, up 11% YoY; expected EPS $2.25 (guidance $2.10-$2.25).
the Board of Directors (the "Board") of the Company approved the appointment of Tom Javitch to serve as the Company’s Interim Chief Financial Officer
Ms. Boratto provided notice of her intent to resign from the Company to pursue another professional opportunity, effective as of the Transition Date, on May 20, 2026.
resigned as a member of the Board effective the same day
the Board of Directors of the Company (the “Board”) has appointed Daniel Heaf to serve as Chief Executive Officer of the Company, effective May 16, 2025
Gina Boswell ceased to serve as Chief Executive Officer of the Company effective as of May 16, 2025
Mr. Heaf will be appointed as a member of the Board effective as of immediately following the conclusion of the Company’s 2025 Annual Meeting of Shareholders
Effective on January 31, 2025, Deon Riley ceased to serve as Chief Human Resources Officer of Bath & Body Works, Inc.
Julie Rosen ceased to serve as President, Retail of Bath & Body Works, Inc. (the “Company”) on September 25, 2024.
On April 20, 2024, Thomas J. Kuhn notified the Board of Directors (the “Board”) of Bath & Body Works, Inc. (the “Company”) of his resignation of service as a director of the Company, effective the same date.
each of Patricia S. Bellinger and Michael G. Morris notified Bath & Body Works, Inc. (the “Company”) of their decision not to stand for re-election to the Company’s Board of Directors following expiration of their current term at the Company’s 2024 Annual Meeting of Stockholders.
each of Patricia S. Bellinger and Michael G. Morris notified Bath & Body Works, Inc. (the “Company”) of their decision not to stand for re-election to the Company’s Board of Directors following expiration of their current term at the Company’s 2024 Annual Meeting of Stockholders.
Wendy C. Arlin will cease serving as Chief Financial Officer effective as of July 29, 2023.
Max materiality 0.85 · Median 0.65 · Most common event earnings